STRO
Sutro Biopharma
NASDAQ: STRO · HEALTHCARE · BIOTECHNOLOGY
$35.39
+2.02% today
Updated 2026-04-29
Market cap
$556.51M
P/E ratio
—
P/S ratio
5.43x
EPS (TTM)
$-22.49
Dividend yield
—
52W range
$7 – $36
Volume
0.2M
Sutro Biopharma (STRO) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-13.15M | $-37.07M | $12.68M | $-65.02M | $-67.80M | $-81.68M | $3.55M | $-111.62M | $-191.54M | $-177.23M |
| Capital expenditures | $4.39M | $3.32M | $1.56M | $3.48M | $7.13M | $15.32M | $7.86M | $4.32M | $3.10M | $1.70M |
| Depreciation | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $968000.00 | $1.39M | $2.87M | $10.31M | $11.92M | $23.24M | $26.30M | $24.91M | $24.69M | $14.01M |
| Free cash flow | $-17.55M | $-40.39M | $11.13M | $-68.50M | $-74.93M | $-97.00M | $-4.31M | $-115.93M | $-194.64M | $-178.93M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $297000.00 | $314000.00 | — | $463000.00 | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $103.28M | $-120.34M | $202.05M | $-175.74M | — | — | — | — |